Promiscuous binding has been considered to be a problem in the design and development of new drugs against a given disease. However, promiscuity in molecular recognition is not all bad news, and scientists are currently taking advantage of the emerging 'promiscuous binding' or 'multi-target approach' in medicinal chemistry.
Bibliographical noteFunding Information:
The author thanks the referees for their useful comments and suggestions, and Asya Varbanova for the review of the manuscript draft. The author’s research is supported by a research stipend granted by the Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota.
- Alzheimer's disease
- Drug design
- Promiscuous drug